- Home
- GMAB vs AKAM Comparison
GMAB vs AKAM Comparison
Compare GMAB & AKAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GMAB | AKAM |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 11.4B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | GMAB | AKAM |
|---|---|---|
| Price | $31.31 | $86.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 16 |
| Target Price | $40.40 | ★ $91.20 |
| AVG Volume (30 Days) | 1.4M | ★ 3.6M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.41 | 0.97 |
| EPS | ★ 25.10 | 3.41 |
| Revenue | $3,845,670,022.00 | ★ $4,133,202,000.00 |
| Revenue This Year | $24.85 | $7.09 |
| Revenue Next Year | $16.67 | $5.26 |
| P/E Ratio | ★ $1.25 | $25.16 |
| Revenue Growth | ★ 29.57 | 4.21 |
| 52 Week Low | $17.24 | $67.51 |
| 52 Week High | $33.65 | $103.75 |
Technical Indicators
Market Signals| Indicator | GMAB | AKAM |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 52.82 |
| Support Level | $30.81 | $85.15 |
| Resistance Level | $32.51 | $87.27 |
| Average True Range (ATR) | 0.65 | 2.17 |
| MACD | -0.03 | -0.70 |
| Stochastic Oscillator | 31.94 | 40.34 |
Price Performance
Historical ComparisonAbout GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.